Valsartan lowers brain beta-amyloid protein levels and improves spatial learning in a mouse model of Alzheimer disease.

Recent epidemiological evidence suggests that some antihypertensive medications may reduce the risk for Alzheimer disease (AD). We screened 55 clinically prescribed antihypertensive medications for AD-modifying activity using primary cortico-hippocampal neuron cultures generated from the Tg2576 AD mouse model. These agents represent all drug classes used for hypertension pharmacotherapy. We identified 7 candidate antihypertensive agents that significantly reduced AD-type beta-amyloid protein (Abeta) accumulation. Through in vitro studies, we found that only 1 of the candidate drugs, valsartan, was capable of attenuating oligomerization of Abeta peptides into high-molecular-weight (HMW) oligomeric peptides, known to be involved in cognitive deterioration. We found that preventive treatment of Tg2576 mice with valsartan significantly reduced AD-type neuropathology and the content of soluble HMW extracellular oligomeric Abeta peptides in the brain. Most importantly, valsartan administration also attenuated the development of Abeta-mediated cognitive deterioration, even when delivered at a dose about 2-fold lower than that used for hypertension treatment in humans. These preclinical studies suggest that certain antihypertensive drugs may have AD-modifying activity and may protect against progressive Abeta-related memory deficits in subjects with AD or in those at high risk of developing AD.

[1]  B. Hyman,et al.  Reversible Memory Loss in a Mouse Transgenic Model of Alzheimer's Disease , 2002, The Journal of Neuroscience.

[2]  Singer Rb.  Stroke in the elderly treated for systolic hypertension (SHEP) part II--mortality. , 1991 .

[3]  P. Zandi,et al.  Antihypertensive medication use and incident Alzheimer disease: the Cache County Study. , 2006, Archives of neurology.

[4]  M. Prince,et al.  Is the cognitive function of older patients affected by antihypertensive treatment? Results from 54 months of the Medical Research Council's treatment trial of hypertension in older adults , 1996, BMJ.

[5]  R. Morris.  Developments of a water-maze procedure for studying spatial learning in the rat , 1984, Journal of Neuroscience Methods.

[6]  D. Morgan.  Mechanisms of Aβ Plaque Clearance following Passive Aβ Immunization , 2006, Neurodegenerative Diseases.

[7]  T. Saibara,et al.  Progressive development of insulin resistance phenotype in male mice with complete aromatase (CYP19) deficiency. , 2003, The Journal of endocrinology.

[8]  B. Winblad,et al.  Low Blood Pressure and Incidence of Dementia in a Very Old Sample: Dependent on Initial Cognition , 1999, Journal of the American Geriatrics Society.

[9]  W. K. Cullen,et al.  Amyloid β protein immunotherapy neutralizes Aβ oligomers that disrupt synaptic plasticity in vivo , 2005, Nature Medicine.

[10]  W. K. Cullen,et al.  Naturally secreted oligomers of amyloid β protein potently inhibit hippocampal long-term potentiation in vivo , 2002, Nature.

[11]  D. Selkoe,et al.  Natural oligomers of the amyloid-β protein specifically disrupt cognitive function , 2005, Nature Neuroscience.

[12]  W. Klein.  Aβ toxicity in Alzheimer’s disease: globular oligomers (ADDLs) as new vaccine and drug targets , 2002, Neurochemistry International.

[13]  P. Hof,et al.  The FASEB Journal express article 10.1096/fj.05-4359fje. Published online September 26, 2005. , 2022 .

[14]  E. Leof,et al.  The FASEB Journal • Research Communication Imatinib mesylate blocks a non-Smad TGF- � pathway and reduces renal fibrogenesis in vivo , 2022 .

[15]  T. Oltersdorf,et al.  Cleavage of amyloid beta peptide during constitutive processing of its precursor. , 1990, Science.

[16]  P. Hof,et al.  A comparative study of histological and immunohistochemical methods for neurofibrillary tangles and senile plaques in Alzheimer's disease , 2004, Acta Neuropathologica.

[17]  D. Morgan.  Mechanisms of A beta plaque clearance following passive A beta immunization. , 2005, Neuro-degenerative diseases.

[18]  D. Rodríguez‐Puyol,et al.  Crosstalk Between Mesangial and Endothelial Cells: Angiotensin II Down-Regulates Endothelin-Converting Enzyme 1 , 2005, Cellular Physiology and Biochemistry.

[19]  S. Estus,et al.  Production of the Alzheimer amyloid beta protein by normal proteolytic processing. , 1992, Science.

[20]  A. Hofman,et al.  The Study on COgnition and Prognosis in the Elderly (SCOPE); outcomes in patients not receiving add-on therapy after randomization , 2004, Journal of hypertension.

[21]  D. Westaway,et al.  Therapeutically effective antibodies against amyloid-β peptide target amyloid-β residues 4–10 and inhibit cytotoxicity and fibrillogenesis , 2002, Nature Medicine.

[22]  A. Hofman,et al.  Antihypertensive drugs and incidence of dementia: the Rotterdam Study , 2001, Neurobiology of Aging.

[23]  T. Tong,et al.  Expression of the Leo1‐like domain of replicative senescence down‐regulated Leo1‐like (RDL) protein promotes senescence of 2BS fibroblasts , 2005, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[24]  J. Birks,et al.  Nimodipine for primary degenerative, mixed and vascular dementia. , 2002, The Cochrane database of systematic reviews.

[25]  P. Hof,et al.  Caloric restriction attenuates β‐amyloid neuropathology in a mouse model of Alzheimer's disease , 2005, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[26]  Patrick R Hof,et al.  Diet‐induced insulin resistance promotes amyloidosis in a transgenic mouse model of Alzheimer's disease , 2004, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[27]  G. Pasinetti,et al.  Role of cyclooxygenase-2 in neuronal cell cycle activity and glutamate-mediated excitotoxicity. , 2002, The Journal of pharmacology and experimental therapeutics.

[28]  Mark Bowlby,et al.  Early-onset behavioral and synaptic deficits in a mouse model of Alzheimer's disease. , 2006, Proceedings of the National Academy of Sciences of the United States of America.

[29]  Michela Gallagher,et al.  A specific amyloid-beta protein assembly in the brain impairs memory. , 2006, Nature.

[30]  S. Yamamoto,et al.  Pharmacological profile of valsartan, a non-peptide angiotensin II type 1 receptor antagonist. 1st communication: antihypertensive effects of valsartan in hypertensive models. , 1997, Arzneimittel-Forschung.

[31]  D. Selkoe,et al.  Amyloid β-peptide is produced by cultured cells during normal metabolism , 1992, Nature.

[32]  W. K. Cullen,et al.  Amyloid beta protein immunotherapy neutralizes Abeta oligomers that disrupt synaptic plasticity in vivo. , 2005, Nature medicine.

[33]  M. Gallagher,et al.  A specific amyloid-β protein assembly in the brain impairs memory , 2006, Nature.

[34]  J. Buxbaum,et al.  Insulin degrading enzyme activity selectively decreases in the hippocampal formation of cases at high risk to develop Alzheimer's disease , 2007, Neurobiology of Aging.

[35]  Jaakko Tuomilehto,et al.  The prevention of dementia with antihypertensive treatment: new evidence from the Systolic Hypertension in Europe (Syst-Eur) study. , 2002 .

[36]  S. Younkin,et al.  Correlative Memory Deficits, Aβ Elevation, and Amyloid Plaques in Transgenic Mice , 1996, Science.

[37]  P. Matsudaira,et al.  Generation of beta-amyloid in the secretory pathway in neuronal and nonneuronal cells. , 1993, Proceedings of the National Academy of Sciences of the United States of America.

[38]  D. Selkoe.  Alzheimer's disease: genes, proteins, and therapy. , 2001, Physiological reviews.

[39]  P. S. St George-Hyslop,et al.  Therapeutically effective antibodies against amyloid-beta peptide target amyloid-beta residues 4-10 and inhibit cytotoxicity and fibrillogenesis. , 2002, Nature medicine.

[40]  A. Hofman,et al.  The Study on Cognition and Prognosis in the Elderly (SCOPE): principal results of a randomized double-blind intervention trial , 2003, Journal of hypertension.

[41]  K. Tanzawa,et al.  Localization of rat endothelin-converting enzyme to vascular endothelial cells and some secretory cells. , 1995, The Biochemical journal.

[42]  D. Westaway,et al.  Cyclohexanehexol inhibitors of Aβ aggregation prevent and reverse Alzheimer phenotype in a mouse model , 2006, Nature Medicine.

[43]  Mikio Shoji,et al.  Age-Dependent Changes in Brain, CSF, and Plasma Amyloid β Protein in the Tg2576 Transgenic Mouse Model of Alzheimer's Disease , 2001, The Journal of Neuroscience.

[44]  L. Hersh,et al.  Insulin-degrading Enzyme Regulates Extracellular Levels of Amyloid β-Protein by Degradation* , 1998, The Journal of Biological Chemistry.